Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, July 2022

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 18 Dimensions

Readers on

mendeley: 20 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 2 X users, with an upper bound of 1,429 followers.

RT @JournalofExper1: Just Published!✅ Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembroli…

13 Jul 2022

Reply Repost Favourite

Just Published!✅ Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers Here the full study 👇 https://t.co/ZcM6yfXjxk #PhaseI #DoseEscalation #Immunotherapy @IREISGuff

12 Jul 2022

Reply Repost Favourite

New article: Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers https://t.co/2SdKgW0zP6 #livercancer #oncology https://t.co/VuJpilfwcc

07 Jul 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.